The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Claire Harrison, MD, deputy chief medical officer at the Guy’s and St. Thomas’ NHS Foundation in the United Kingdom, discusses results from the phase 1 trial of INCA033989 in CALR-mutant myelofibrosis, which were presented at the 2026 European Hematology Association Congress in Stockholm, Sweden.
The clinical approval was based on data from the international phase 2 L-MIND trial and the domestic phase 1b/2 J-MIND trial in Japan. In the international study, patients treated with the tafasitamab combination achieved an overall response rate of 58.8% with a 41.3% complete response rate.
The MajesTEC-3 trial compared teclistamab plus daratumumab with standard daratumumab plus dexamethasone and pomalidomide or bortezomib (DPd/DVd). In the previous primary analysis, teclistamab plus daratumumab met the primary PFS endpoints and all key secondary endpoints including CR or better, MRD negativity, and overall survival rates.
Taiwan’s Ministry of Health and Welfare has approved ropeginterferon alfa-2b-njft (BESREMi) for adult patients with essential thrombocythemia, according to PharmaEssentia, the manufacturer of the drug.
In this SOHO Insider interview from the 2026 AACR Annual Meeting, John DiPersio, MD, PhD, president of the Society of Hematologic Oncology, shares what he believes the future of blood cancers hold and how AI platforms will contribute to future discoveries.
Andrew Kuykendall, MD, an associate member from Moffitt Cancer Center, discusses updated data from the phase 2 RALLY-MF trial. The trial evaluated DISC-0974 in patients with myelofibrosis and anemia. DISC-0974 is a first-in-class monoclonal antibody designed to block hemojuvelin.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
![Insider_YT_Feature_Pannunzio_CLFR2_400x400[15]](https://sohoinsider.com/wp-content/uploads/2026/06/Insider_YT_Feature_Pannunzio_CLFR2_400x40015.png)
